Table 2. Glycopeptides Displaying Statistically Significantly Different Abundances in Both Discovery and Validation Sample Sets.

marker	healthy control/HCC (multiplicative difference)	healthy control/HCC (p-value)	healthy control/HCC (FDR)	benign hepatic mass/HCC (multiplicative difference)	benign hepatic mass/HCC (p-value)	benign hepatic mass/HCC (FDR)
A2MG (1424) – 5402	1.57	<0.001	<0.001	1.2	0.01	0.214
A2MG (247) – 5200	0.65	<0.001	<0.001	0.62	<0.001	0.005
A2MG (247) – 5401	0.89	0.04	0.089	0.84	0.012	0.218
A2MG (55) – 5411	0.69	<0.001	<0.001	0.66	<0.001	0.007
A2MG (55) – 5412	0.67	<0.001	<0.001	0.67	<0.001	0.009
A2MG (869) – 5200	0.74	<0.001	<0.001	0.82	0.003	0.107
A2MG (869) – 6200	0.68	<0.001	<0.001	0.79	0.002	0.092
A2MG (869) – 6300	0.62	<0.001	<0.001	0.63	<0.001	0.005
A2MG (991) – 5402	0.72	0.001	0.004	0.61	<0.001	0.007
AFAM (33) – 5402	1.33	0.002	0.006	1.12	0.049	0.348
HPT (207 and 211) – 5401 and 5402	0.55	<0.001	<0.001	0.71	0.032	0.280
IGG1 (297) – 5411	1.54	0.037	0.078	1.28	0.047	0.340
A2MG – AIGYLNTGYQR	1.26	0.014	0.036	1.95	0.003	0.107
A2MG – TEHPFTVEEFVLPK	1.26	0.029	0.064	1.97	0.003	0.098